These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 14644022)

  • 1. Medical treatment in acromegaly.
    Paisley AN; Trainer PJ
    Curr Opin Pharmacol; 2003 Dec; 3(6):672-7. PubMed ID: 14644022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegvisomant: an advance in clinical efficacy in acromegaly.
    Stewart PM
    Eur J Endocrinol; 2003 Apr; 148 Suppl 2():S27-32. PubMed ID: 12670298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with pegvisomant in the treatment of acromegaly.
    Drake WM
    Growth Horm IGF Res; 2001 Jun; 11 Suppl A():S111-4. PubMed ID: 11527081
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How effective are current therapies for acromegaly?
    Freda PU
    Growth Horm IGF Res; 2003 Aug; 13 Suppl A():S144-51. PubMed ID: 12914744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Additional metabolic effects of adding GH receptor antagonist to long-acting somatostatin analog in patients with active acromegaly.
    Jawiarczyk A; Kałuzny M; Bolanowski M; Bednarek-Tupikowska G
    Neuro Endocrinol Lett; 2008 Aug; 29(4):571-6. PubMed ID: 18766168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Possibilities of medical treatment in acromegaly].
    Cáp J; Nemecek S; Rezácová M; Cerman J
    Cas Lek Cesk; 2005; 144 Suppl 3():33-4, 36-7. PubMed ID: 16335261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological approach to the treatment of acromegaly.
    Ezzat S
    Neurosurg Focus; 2004 Apr; 16(4):E3. PubMed ID: 15191332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The place of pegvisomant in the management of acromegaly.
    Parkinson C; Trainer PJ
    Expert Opin Investig Drugs; 2001 Sep; 10(9):1725-35. PubMed ID: 11772281
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
    Ezzat S; Gaspo R; Serri O; Ur E; Chik CL
    Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment of acromegaly.
    Holdaway IM
    Horm Res; 2004; 62 Suppl 3():79-92. PubMed ID: 15539805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease activity in acromegaly may be assessed 6 weeks after discontinuation of pegvisomant.
    Drake WM; Loureiro RA; Parkinson C; Monson JP; Besser GM; Trainer PJ
    Eur J Endocrinol; 2005 Jan; 152(1):47-51. PubMed ID: 15762186
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of growth hormone-receptor antagonism in relation to acromegaly.
    Ayuk J; Sheppard MC
    Expert Opin Pharmacother; 2004 Nov; 5(11):2279-85. PubMed ID: 15500374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegvisomant in the treatment of acromegaly.
    Parkinson C; Scarlett JA; Trainer PJ
    Adv Drug Deliv Rev; 2003 Sep; 55(10):1303-14. PubMed ID: 14499709
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Successful treatment of resistant acromegaly with a growth hormone receptor antagonist.
    Drake WM; Parkinson C; Akker SA; Monson JP; Besser GM; Trainer PJ
    Eur J Endocrinol; 2001 Oct; 145(4):451-6. PubMed ID: 11581004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current and future medical treatments for patients with acromegaly.
    Maffezzoni F; Formenti AM; Mazziotti G; Frara S; Giustina A
    Expert Opin Pharmacother; 2016 Aug; 17(12):1631-42. PubMed ID: 27352098
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cabergoline in acromegaly.
    Kuhn E; Chanson P
    Pituitary; 2017 Feb; 20(1):121-128. PubMed ID: 28025719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist.
    Jørgensen JO; Feldt-Rasmussen U; Frystyk J; Chen JW; Kristensen LØ; Hagen C; Ørskov H
    J Clin Endocrinol Metab; 2005 Oct; 90(10):5627-31. PubMed ID: 16046586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly.
    Selvarajah D; Webster J; Ross R; Newell-Price J
    Eur J Endocrinol; 2005 Apr; 152(4):569-74. PubMed ID: 15817912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Therapeutic management of acromegaly].
    Metzner C; Hadziselimovic S; Grafe I; Nawroth P; Kasperk C
    Med Klin (Munich); 2006 Jan; 101(1):15-23. PubMed ID: 16418810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.